A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

New research suggests that a majority of patients with endometrial cancer may have tumors with a HER2 score of 2+ or higher.

(JAMA Network Open) A phase III trial of the antibody-drug conjugate patritumab deruxtecan in non-small cell lung cancer met the primary endpoint of progression-free survival, although two deaths not ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.